Pharmacy middlemen sue to stop rebate transparency
An industry group representing powerful drug middlemen has gone to court to stop a federal rule intended to bring transparency to rebates middlemen get from manufacturers. The middlemen are arguing that the rule, initiated by the Trump administration, will increase drug costs. But the group’s critics say that secretive rebates are a primary driver of […]
Drug-pricing reform might fall victim to infrastructure negotiations
As lawmakers attempt to salvage a bipartisan infrastructure package, new rules intended to crack down on secretive prescription-drug transactions might fall by the wayside.